Web Results

www.pulmonaryfibrosis.org/life-with-pf/clinical-trials/pipeline

Drug Development Pipeline - PF & IPF. Welcome to the PF Drug Development Pipeline where you can learn about the latest in drug development for PF-related  ...

pubmed.ncbi.nlm.nih.gov/32538186

Jun 24, 2020 ... The approval of pirfenidone and nintedanib has fueled IPF drug discovery and development. New drugs are likely to reach the clinic in the near ...

erj.ersjournals.com/content/45/5/1218

Efficient IPF drug development is needed to ensure unmet medical need isn't ... pulmonary fibrosis (IPF) remains a high-risk disease area for drug development.

www.ajmc.com/view/emerging-therapeutic-innovations-for-treatment-of-idiopathic-pulmonary-fibrosis

Jan 17, 2020 ... Study authors note that while the recent introduction of antifibrotic drugs pirfenidone and ... The development of biomarkers to personalize therapy for IPF is a...

innovations.clevelandclinic.org/Programs/Top-10-Medical-Innovations/Top-10-for-2015/8-New-Medications-for-Idiopathic-Pulmonary-Fibros

#8 New Medications for Idiopathic Pulmonary Fibrosis ... Some people develop IPF after receiving radiation therapy for lung or breast cancer, while others ...

bmcmedicine.biomedcentral.com/articles/10.1186/s12916-015-0480-7

Sep 24, 2015 ... IPF drug discovery between present and future. To date, 12 medicinal products, most in preclinical phase of development, have obtained orphan ...

www.astrazeneca.com/media-centre/press-releases/2019/us-fda-grants-saracatinib-orphan-drug-designation-for-idiopathic-pulmonary-fibrosis-18032019.html

Mar 18, 2019 ... Saracatinib has completed Phase I development. IPF is a chronic, progressive, irreversible and usually fatal interstitial lung disease1 which ...

thorax.bmj.com/content/71/8/675

Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease that ... Notably, repositioning of drugs can shorten drug development time by >50% as ...

www.biopharmadive.com/news/roche-promedior-acquisition-ipf-fibrosis/567447

Nov 15, 2019 ... Roche's Esbriet is one of two drugs approved to treat IPF, and came under the ... as it continues developing PRM-151 for IPF and myelofibrosis.

www.verywellhealth.com/research-advances-in-idiopathic-pulmonary-fibrosis-4147729

4 These genetic markers are providing researchers with specific targets for drug development in the treatment of IPF. In a few years, drugs specifically “tailored” to  ...